학술논문
A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM's “pick a winner” trial, with the impact of somatic mutations
Document Type
Article
Author
Adès, L.; Fenaux, P.; Duployez, N.; Preudhomme, C.; Guerci-Bresler, A.; Laribi, K.; Peterlin, P.; Vey, N.; Thepot, S.; Wickenhauser, S.; Zerazhi, H.; Stamatoullas, A.; Wattel, E.; Recher, C.; Beyne-Rauzy, O.; Toma, A.; Dimicoli-Salazar, S.; Braun, T.; Marolleau, J.-P.; Cheze, S.; Park, S.; Cluzeau, T.; Nimubona, S.; Bordessoule, D.; Benramdane, R.; Quesnel, B.; Amé, S.; de Botton, S.; Chermat, F.; Chevret, S.
Source
In: British Journal of Haematology . (British Journal of Haematology, August 2022, 198(3):535-544)
Subject
Language
English
ISSN
13652141
00071048
00071048